Targeting the A2B adenosine receptor for immunoprevention of pancreatic cancer
Active Awarded Last action
- Contract number
- 75N91023F00003
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,272,481
Award facts
- Opportunity
-
- TORFP2023E06 Solicitation number
- Contract value 100% obligated
- $1,272,481.00 Current and potential, with all options
- Completion date 89% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $678,909 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $593,572 |
About this award
This federal contract award, valued at $1,272,481.00, was issued by the National Cancer Institute to The University of Texas M.D. Anderson Cancer Center, a child entity of the University of Texas System. The contract is part of the "PREVENT Preclinical Drug Development Program (PREVENT)" and is focused on "TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER." It is a firm fixed-price delivery order contract with a completion date of March 14, 2027. The award does not have a set-aside designation. As a leading academic cancer research and treatment institution, M.D. Anderson Cancer Center has extensive experience in conducting federally-funded medical research and providing specialized services to agencies like the National Institutes of Health.
Quick answers
Who was awarded contract 75N91023F00003?
75N91023F00003 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 15, 2023.
How much is contract 75N91023F00003 worth?
The government has obligated $1,272,481 on 75N91023F00003.
Is contract 75N91023F00003 an order under another contract?
Yes. 75N91023F00003 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91023F00003 competed?
The extent of competition for 75N91023F00003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award